Document is current

Article History

Received: 17 November 2020

Accepted: 23 March 2021

First Online: 13 April 2021

Declarations

:

: This study has been approved by the Ethics Committee of the Ludwig-Maximilian-University Munich (approval number 048–08). The BC specimens were obtained in clinically indicated surgeries. When the current study was performed, all diagnostic procedures were completed, and the patients’ data were anonymized. The ethical principles adopted in the Declaration of Helsinki 1975 have been respected. As per declaration of our ethics committee, no written informed consent of the participants or permission to publish is needed given the circumstances described above. Researchers were blinded from patient data during experimental and statistical analysis.

: All authors read the manuscript and agreed to the publication of the manuscript.

: Thomas Kolben holds stock of Roche AG and is relative employed at Roche AG. Anna Hester has received a research grant from the “Walter Schulz” foundation and advisory board, speech honoraria, and travel expenses from Roche and Pfizer. Research support, advisory board, honoraria, and travel expenses from AstraZeneca, Clovis, Medac, MSD, Novartis, PharmaMar, Roche, Sensor Kinesis, Tesaro, and Teva have been received by Sven Mahner. Fabian Trillsch declares research support, advisory board, honoraria, and travel expenses from AstraZeneca, Medac, PharmaMar, Roche, and Tesaro. Doris Mayr declares advisory board and investigator meeting honoraria from AstraZeneca, Novartis, and Merck All other authors declare no conflict of interest.